Skip to main content

Table 11 Selected phase I-II clinical trials conducted with AT-101 as a single (−single-) or combined therapeutic on untreated/pre-treated patients with Carboplatin (CARB), Paclitaxel (PAC), Cisplatin (CIS), Etoposide (ETOP), Luteinizing Hormone Receptor Hormone (LHRH) agonist, Bicalutamide (BIC) against Advanced Solid Tumors (AST), Giant Cell Glioblastoma (GCG), Adrenocortical (ADC), Solid Tumors (ST), Small Cell lung Cancer (SCLC) and Metastatic Prostate Cancer (MPC) are highlighted for Maximum Tolerated Doses (MTD). Side effects are abbreviated as ADP (Abdominal Pain), Neut (Neutropenia), Throm (Thrombocytopenia), Gastrointestinal symptoms (GI), Fatigue (FAT), Anemia (Anem) and Nausea (Nau). Objective Response Rates (ORR), Complete Responses (CR), Partial Responses (PR), Prostate-Specific Antigen levels (PSA) and percentage patients (%) from the whole group experiencing disease stabilization effects are also highlighted (Stab.). The clinical trials reference numbers are highlighted in bold (left column), and the corresponding references highlighted in the column on the right (Ref). Unavailable data is highlighted by ‘-‘

From: BH3-mimetics: recent developments in cancer therapy

AT-101 Phase Patients Patients Combined Disease Adverse Effects ORR Stab. Ref
NCT00891072 I 24 Pre-treated CARB/PAC AST ADP/Neut/Throm 4.16% CR; 16.66% PR 33% [401]
NCT00540722 II 56 Untreated (3 wks) -single- GCG GI/FAT
NCT00848016 II 29 -single- ADC Anem/Naus/FAT
NCT00544596 I 27 Untreated (4 wks) CIS/ETOP ST/SCLC
NCT00773955 II 14 Pre-treated -single- SCLC Anem/GI 0% CR; 0% PR
NCT00666666 II 55 Untreated (4 wks) LHRH/BIC MPC Anem/GI/AT 18–60% Decreased PSA